Larimar Therapeutics Inc (LRMR) concluded trading on Thursday at a closing price of $2.40, with 2.17 million shares of worth about $5.2 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -62.56% during that period and on March 27, 2025 the price saw a gain of about 6.67%. Currently the company’s common shares owned by public are about 63.82M shares, out of which, 36.59M shares are available for trading.
Stock saw a price change of -4.38% in past 5 days and over the past one month there was a price change of -18.09%. Year-to-date (YTD), LRMR shares are showing a performance of -37.98% which decreased to -68.34% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.19 but also hit the highest price of $11.20 during that period. The average intraday trading volume for Larimar Therapeutics Inc shares is 647.16K. The stock is currently trading -9.33% below its 20-day simple moving average (SMA20), while that difference is down -22.49% for SMA50 and it goes to -61.20% lower than SMA200.
Larimar Therapeutics Inc (NASDAQ: LRMR) currently have 63.82M outstanding shares and institutions hold larger chunk of about 59.05% of that.
The stock has a current market capitalization of $153.67M and its 3Y-monthly beta is at 0.87. It has posted earnings per share of -$1.31 in the same period. It has Quick Ratio of 8.02 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LRMR, volatility over the week remained 8.74% while standing at 8.58% over the month.
Stock’s fiscal year EPS is expected to drop by -38.94% while it is estimated to decrease by -11.26% in next year. EPS is likely to shrink at an annualized rate of -7.48% for next 5-years, compared to annual growth of 50.78% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Truist on January 29, 2025 offering a Buy rating for the stock and assigned a target price of $18 to it. Coverage by Oppenheimer stated Larimar Therapeutics Inc (LRMR) stock as an Outperform in their note to investors on October 16, 2024, suggesting a price target of $26 for the stock. On October 03, 2024, Wedbush Initiated their recommendations, while on October 02, 2024, H.C. Wainwright Initiated their ratings for the stock with a price target of $15. Stock get an Outperform rating from Robert W. Baird on September 04, 2024.
